POLR3B

POLR3B encodes the second largest catalytic subunit (RPC2) of the 17-subunit RNA Polymerase III complex, forming the active center with RPC1 (POLR3A) to transcribe small noncoding RNAs including tRNAs and 5S rRNA (PMID:22036172). Its interaction with the POLR3K (Rpc11) subunit is required for Pol III function, as demonstrated by cross-species rescue experiments, and proper Pol III complex assembly depends on the PAQosome chaperone machinery (PMID:18044988, PMID:36451185). POLR3B is essential for proliferating tissues: conditional loss in mouse intestinal epithelium abolishes crypt maintenance via loss of Wnt signaling (PMID:28090567), and in oligodendrocyte precursors it impairs proliferation and differentiation, causing severe hypomyelination characteristic of POLR3-related leukodystrophy (HLD8), where biallelic loss-of-function variants disrupt complex assembly while de novo heterozygous missense variants cause aberrant inter-subunit associations representing a mechanistically distinct dominant pathogenic mode (PMID:37635302, PMID:33417887).

1. 2007 High

   Establishing that POLR3B physically links the Pol III catalytic core to the POLR3K (Rpc11) subunit answered how RNA cleavage-competent Pol III is assembled, showing that a specific 41-amino-acid region of RPC2 is required for Rpc11 incorporation into the complex.

   Evidence Zebrafish polr3b splice-site mutant (slim jim) combined with engineered S. pombe rpc2-Δ yeast strain; genetic rescue by polr3k overexpression across two organisms

   PMID:18044988

   Open questions at the time

   • Structural basis of the RPC2–Rpc11 interaction at atomic resolution was not determined
   • Whether this interaction is regulated or constitutive in vivo remains unknown
2. 2011 High

   Identification of biallelic POLR3B mutations in leukodystrophy patients established that POLR3B loss of function causes human disease, with splice-site mutations leading to exon skipping and nonsense mutations triggering NMD, linking the Pol III catalytic subunit to central nervous system myelination.

   Evidence Whole-exome sequencing of leukodystrophy families; RT-PCR and NMD analysis of patient cells

   PMID:22036171 PMID:22036172

   Open questions at the time

   • Cell-type-specific vulnerability (why oligodendrocytes are disproportionately affected) was not explained
   • Quantitative impact on Pol III transcriptome was not measured
3. 2016 High

   Demonstrating that Polr3b is cell-autonomously required for intestinal crypt maintenance revealed an essential proliferative role outside the nervous system, with loss causing Wnt signaling collapse and apoptosis in transit-amplifying compartments.

   Evidence VillinCre conditional knockout in mice with Rosa26-YFP lineage tracing and enteroid culture

   PMID:28090567

   Open questions at the time

   • Whether the intestinal phenotype reflects global tRNA insufficiency or loss of specific Pol III transcripts is unknown
   • Relevance to human intestinal pathology in POLR3B patients not established
4. 2019 High

   Showing that the leukodystrophy-causative R103H mutation severely impairs Pol III complex assembly and causes embryonic lethality in homozygous mice established that defective complex biogenesis, not just reduced catalytic activity, is a primary pathogenic mechanism.

   Evidence Affinity purification–mass spectrometry in human cell lines; R103H homozygous mouse lethality at E9.5

   PMID:31221184

   Open questions at the time

   • Which specific assembly intermediate is disrupted by R103H was not resolved
   • No conditional or heterozygous phenotyping in neural lineages was performed
5. 2021 Medium

   Discovery that de novo heterozygous POLR3B missense variants cause aberrant inter-subunit associations — rather than global assembly loss — established a mechanistically distinct dominant-negative or gain-of-function pathogenic mode separate from biallelic loss of function.

   Evidence Proteomic analysis and structural modeling of de novo variants

   PMID:33417887

   Open questions at the time

   • Not independently replicated in a second cohort or lab
   • Functional consequence on Pol III transcription not directly measured
   • Precise nature of aberrant subunit interactions (stoichiometry, stability) unresolved
6. 2022 Medium

   Resolving the R103H assembly defect to specific stages and identifying the PAQosome as a chaperone for Pol III biogenesis opened a therapeutic axis, as riluzole partially corrected the assembly defect.

   Evidence Mass spectrometry-based assembly assay, PAQosome interaction analysis, riluzole drug treatment in cell lines

   PMID:36451185

   Open questions at the time

   • Riluzole mechanism of rescue not defined at molecular level
   • PAQosome contribution to Pol III biogenesis not validated in vivo
   • Whether other disease variants respond similarly is untested
7. 2022 Medium

   Demonstrating that the R550X nonsense mutation mislocalizes truncated POLR3B protein to lysosomes and diminishes mTOR signaling in oligodendroglial precursors provided a mechanistic link between Pol III deficiency and impaired oligodendrocyte differentiation.

   Evidence FBD-102b oligodendroglial precursor cell model, immunofluorescence, mTOR signaling assay, ibuprofen rescue

   PMID:35225888

   Open questions at the time

   • Single cell-line model without in vivo confirmation
   • Whether lysosomal mislocalization occurs with other truncating mutations unknown
   • mTOR pathway involvement not validated in patient-derived cells
8. 2023 High

   A conditional mouse model expressing POLR3BΔ10 in oligodendrocyte precursors demonstrated that Pol III assembly defects directly impair OPC proliferation and differentiation, producing severe hypomyelination and establishing the cell-autonomous basis of POLR3-related leukodystrophy.

   Evidence Pdgfrα-Cre/ERT conditional knock-in mouse; AP-MS, lineage tracing, spectral confocal reflectance microscopy, ex vivo MRI

   PMID:37635302

   Open questions at the time

   • Specific Pol III transcripts limiting OPC differentiation not identified
   • Whether mature oligodendrocytes are also vulnerable to POLR3B deficiency is untested
9. 2024 Medium

   Characterization of a mis-splicing variant revealed that POLR3B deficiency differentially affects tRNA genes based on terminator strength, causes compensatory POLR3E upregulation, and generates tRF-1/tRF-3 ratio shifts as potential biomarkers, providing the first detailed picture of how reduced Pol III activity reshapes the small noncoding transcriptome.

   Evidence (preprint) Genome-edited HEK293 cells, small-RNAseq, patient fibroblast RNA analysis, La-knockdown, mass spectrometry

   PMID:38410490

   Open questions at the time

   • Preprint not yet peer-reviewed
   • tRF biomarker utility not validated in an independent patient cohort
   • Whether terminator-strength-dependent deficiency is general across POLR3B variants is unknown

• The identity of the specific Pol III transcripts whose reduction most critically drives oligodendrocyte precursor failure — and whether therapeutic restoration of individual transcripts or chaperone-assisted complex assembly can rescue myelination in vivo — remains the central open question.
• No single-cell Pol III transcriptome profiling during myelinogenesis
• No in vivo pharmacological rescue of hypomyelination demonstrated
• Structural basis of disease-variant-specific assembly defects not resolved at atomic level